Amylyx's old ALS drug fails in another neuro disease, focus turns to GLP-1

For all intents and purposes, Amylyx is now a GLP-1 biotech. The company's now-withdrawn ALS drug, branded as Relyvrio and codenamed AMX0035, failed a Phase 2b study for a separate rare neurological disease called progressive ...